| Edward Su-chong Lee, MD | |
|
1140 W La Veta Ave, Ste. 520, Orange, CA 92868-4225 | |
| (714) 543-2000 | |
| Not Available |
| Full Name | Edward Su-chong Lee |
|---|---|
| Gender | Male |
| Speciality | Otolaryngology |
| Experience | 29 Years |
| Location | 1140 W La Veta Ave, Orange, California |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1114926672 | NPI | - | NPPES |
| 00A626920 | Medicaid | CA | |
| 00A626920 | Other | BLUE SHIELD OF CA | |
| P00002597 | Other | RAILROAD MEDICARE |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Y00000X | Otolaryngology | A62692 (California) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| St Joseph Hospital | Orange, CA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Entrust Medical Corporation | 1355235110 | 6 |
News Archive
A relatively new tax credit is available to certain small businesses and charities to help offset the cost of providing health insurance to their workers. But tens of thousands of businesses in Minnesota and across the nation are leaving money on the table, according to the U.S. Treasury Department.
A protein called ROBO1 may delay the progression of breast cancer, according to a paper published in The Journal of Cell Biology. The study, "Loss of miR-203 regulates cell shape and matrix adhesion through ROBO1/Rac/FAK in response to stiffness" by Lily Thao-Nhi Le and colleagues, identifies a signaling pathway that may protect breast cells from the tumorigenic effects of stiff extracellular matrices.
Adamas Pharmaceuticals, Inc., a privately held company, announced today that it has entered into a Cooperative Research and Development Agreement (CRADA) with the United States Naval Health Research Center for preclinical studies evaluating Adamas' triple combination antiviral drug (TCAD) therapy for influenza A, including novel influenza A/H1N1. TCAD therapy includes Adamas' investigational proprietary fixed-dose oral combination drug, to be administered adjunctively with a neuraminidase inhibitor, including Tamiflu (oseltamivir phosphate, Roche).
Parkinson's disease is caused by the degeneration of neurons in the midbrain. The mechanisms leading to the loss of these neurons, however, are largely unknown. Recent research revealed that about ten per cent of cases are caused by defects in so-called Parkinson-associated genes. Furthermore, mitochondria, the cellular powerhouses, seem to play a major role. New results from researchers at the LMU Munich under the lead of associate professor Dr. Konstanze Winklhofer and Professor Christian Haass connect both phenomena, showing that two Parkinson genes maintain the function of mitochondria.
› Verified 1 days ago
| Entity Name | Entrust Medical Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1922090372 PECOS PAC ID: 1355235110 Enrollment ID: O20040211001257 |
News Archive
A relatively new tax credit is available to certain small businesses and charities to help offset the cost of providing health insurance to their workers. But tens of thousands of businesses in Minnesota and across the nation are leaving money on the table, according to the U.S. Treasury Department.
A protein called ROBO1 may delay the progression of breast cancer, according to a paper published in The Journal of Cell Biology. The study, "Loss of miR-203 regulates cell shape and matrix adhesion through ROBO1/Rac/FAK in response to stiffness" by Lily Thao-Nhi Le and colleagues, identifies a signaling pathway that may protect breast cells from the tumorigenic effects of stiff extracellular matrices.
Adamas Pharmaceuticals, Inc., a privately held company, announced today that it has entered into a Cooperative Research and Development Agreement (CRADA) with the United States Naval Health Research Center for preclinical studies evaluating Adamas' triple combination antiviral drug (TCAD) therapy for influenza A, including novel influenza A/H1N1. TCAD therapy includes Adamas' investigational proprietary fixed-dose oral combination drug, to be administered adjunctively with a neuraminidase inhibitor, including Tamiflu (oseltamivir phosphate, Roche).
Parkinson's disease is caused by the degeneration of neurons in the midbrain. The mechanisms leading to the loss of these neurons, however, are largely unknown. Recent research revealed that about ten per cent of cases are caused by defects in so-called Parkinson-associated genes. Furthermore, mitochondria, the cellular powerhouses, seem to play a major role. New results from researchers at the LMU Munich under the lead of associate professor Dr. Konstanze Winklhofer and Professor Christian Haass connect both phenomena, showing that two Parkinson genes maintain the function of mitochondria.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Edward Su-chong Lee, MD Po Box 5971, Orange, CA 92863-5971 Ph: (714) 571-5000 | Edward Su-chong Lee, MD 1140 W La Veta Ave, Ste. 520, Orange, CA 92868-4225 Ph: (714) 543-2000 |
News Archive
A relatively new tax credit is available to certain small businesses and charities to help offset the cost of providing health insurance to their workers. But tens of thousands of businesses in Minnesota and across the nation are leaving money on the table, according to the U.S. Treasury Department.
A protein called ROBO1 may delay the progression of breast cancer, according to a paper published in The Journal of Cell Biology. The study, "Loss of miR-203 regulates cell shape and matrix adhesion through ROBO1/Rac/FAK in response to stiffness" by Lily Thao-Nhi Le and colleagues, identifies a signaling pathway that may protect breast cells from the tumorigenic effects of stiff extracellular matrices.
Adamas Pharmaceuticals, Inc., a privately held company, announced today that it has entered into a Cooperative Research and Development Agreement (CRADA) with the United States Naval Health Research Center for preclinical studies evaluating Adamas' triple combination antiviral drug (TCAD) therapy for influenza A, including novel influenza A/H1N1. TCAD therapy includes Adamas' investigational proprietary fixed-dose oral combination drug, to be administered adjunctively with a neuraminidase inhibitor, including Tamiflu (oseltamivir phosphate, Roche).
Parkinson's disease is caused by the degeneration of neurons in the midbrain. The mechanisms leading to the loss of these neurons, however, are largely unknown. Recent research revealed that about ten per cent of cases are caused by defects in so-called Parkinson-associated genes. Furthermore, mitochondria, the cellular powerhouses, seem to play a major role. New results from researchers at the LMU Munich under the lead of associate professor Dr. Konstanze Winklhofer and Professor Christian Haass connect both phenomena, showing that two Parkinson genes maintain the function of mitochondria.
› Verified 1 days ago
Roger L Crumley, MD Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: Uci Medical Center, 101 The City Drive South, Orange, CA 92868 Phone: 714-456-2986 | |
Gurpreet Singh Ahuja, MD Otolaryngology Medicare: Medicare Enrolled Practice Location: 1010 W La Veta Ave, Suite 640, Orange, CA 92868 Phone: 714-633-4020 Fax: 714-953-5462 | |
Dr. William Armstrong, MD Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 101 The City Dr S, Orange, CA 92868 Phone: 714-880-7812 | |
Dr. William Clay Cohen, DO Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 1010 W La Veta Ave Ste 445, Orange, CA 92868 Phone: 714-628-1313 Fax: 714-628-1319 | |
Dr. Dimitry B Goufman, M.D. Otolaryngology Medicare: May Accept Medicare Assignments Practice Location: 302 West Laveta Ave., Suite 201, Orange, CA 92866 Phone: 714-835-4404 Fax: 714-532-6563 | |
Dr. Sunil Verma, M.D. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 101 The City Drive South Bldg 56 Ste 500, Orange, CA 92868 Phone: 714-456-5753 Fax: 608-263-6199 |